Conception and demonstration of a new pathology device. Initially, a non-invasive glucometer for the mass market, to extend the use of the device to facilitate the diagnosis and screening for multiple other diseases and disorders. These inventions and developments have been protected by patent.
Field of the Inventions and Development
The primary development of a nanotechnology device that can transmit a particular set of defined frequency signals through the tissue. This development represents the confluence of at least two separate industries; their disciplines, technical approaches, and processes. The aim is to produce a miniature, low- power, no-moving-parts, no-consumable instrument. This device may display the results on itself or be able to transmit them to other devices such as cell phones or computers. These efforts will result in a non-invasive measuring device that will become a commercial market standard; technologically unsurpassed for decades.
The spectrometer components are all very small and can be placed into a small device that can be clipped onto the tissues of, for example, ear or other skin folds. The device transmits the signal through the tissue and the receptor picks up the transmission signatures of the various molecules within the tissue being assessed. A microprocessor then selects the various signals and these are displayed on the output display on the device and alternatively can be sent via Bluetooth or other signal method to a cell phone or computer for display and storage. The applications for this type of device, which takes the path lab to the patient, will only be limited by the ability to detect the various molecules and the software detection methods used.
Potential Usages of the Device
The initial drive will be to place a non-invasive self-contained glucometer onto the market. The glucometer could be used to measure single-point assessments but also continuous assessments. The device could therefore be used to measure not only a single point blood glucose but also a glucose tolerance response. If appropriate signatures can be acquired the device could also monitor other important biochemical variables such as glycated hemoglobin and polyol pathway components. Thus this device could be the first comprehensive diabetes assessment device that is also non-invasive, which would have a market size in the U.S. in excess of 20 million units.
Multiple other potentially developable usages of the device include monitoring drug trials, normal pathology scanning for a health care professional, disease specific monitoring available to the general public, such as cholesterol and drug dosage timing. This device has immense potential for development as a scanning diagnostic tool and is likely to allow a more speedy diagnosis of diseases as it will expedite the knowledge available to clinicians.